Point-of-Care Diagnostics Market for Infectious Diseases, 2030

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- The "Point-of-Care Diagnostics Market for Infectious Diseases by Indication, Type of Technology and Geography: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The 'Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025' report features an extensive study on point-of-care diagnostics that are either commercialized or are under development for diagnosis of different types of infections. In addition, it features an elaborate discussion on the likely future opportunity associated with such tools, over the next five years.

According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide. Moreover, the pathogens responsible for causing these diseases are known to undergo selective mutations, which make them resistant to commonly used antibiotics.

This impedes the effective treatment of the aforementioned clinical conditions. Since the pathophysiology of such diseases is known to evolve with time, better diagnostic tools with high sensitivity and specificity are required for timely diagnosis and better treatment related decision-making. For diseases of bacterial origin, diagnosis is based on culturing the pathogen; this is considered the current gold standard. Although these methods are highly specific, they are time consuming, requiring three to five days for detecting the responsible pathogen.

On the other hand, in case of viral infections, molecular diagnostic platforms, such as next generation sequencing and real-time polymerase chain reactions, are typically used. However, these molecular level analytical techniques are expensive, complicated, and generally inaccessible in resource-limited settings.

Point-of-care diagnostics have shown to reduce the reliance on presumptive treatment, thereby, helping curb the inappropriate use of antibiotics. Till date, point-of-care diagnostics are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis. In future, we expect such tests / assays to dominate the in vitro diagnostics market.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as number of available / under development products, average price of point-of-care tests and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2020-2025.

The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's growth.

Amongst other elements, the report includes:

    --  A detailed review of the overall landscape of point-of-care diagnostics
        for COVID-19, providing information on current development status of
        point-of-care diagnostics (under development, research use only, and
        available), type of product (test and device / platform), type of
        technology (fluorescence immunoassay, lateral flow, molecular
        diagnostics, solid phase, vertical flow, and others), type of sample
        (blood, nasal / nasopharyngeal secretions, sputum, urine, and others),
        sensitivity range (&lessThan;90%, 90-95%, and >95%), specificity range
        (&lessThan;90%, 90-95%, and >95%), and turnaround time (?5 minutes,
        >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report
        presents the details of the companies developing these point-of-care
        diagnostics, including information on year of establishment, company
        size and location of headquarters.
    --  A detailed review of the overall landscape of Point-of-Care Diagnostics
        for tropical diseases, providing information on current development
        status of point-of-care diagnostics (under development, research use
        only, and available), type of product (test and device / platform), type
        of technology (flow-through, fluorescence immunoassay, lateral flow,
        molecular diagnostics, solid phase, and others), target disease
        indication (chikungunya, dengue, Ebola, malaria, and zika), type of
        sample (blood, sputum, and urine), sensitivity range (&lessThan;90%,
        90-95%, and >95%), specificity range (&lessThan;90%, 90-95%, and >95%),
        and turnaround time (-5 minutes, >5-15 minutes, >15-30 minutes, and >30
        minutes). In addition, the report presents the details of the companies
        developing these point-of-care diagnostics, including information on
        year of establishment, company size and location of headquarters.
    --  A detailed review of the overall landscape of point-of-care diagnostics
        for respiratory infections, providing information on current development
        status of point-of-care diagnostics (under development, research use
        only, and available), type of product (test and device / platform), type
        of technology (fluorescence immunoassay, lateral flow, molecular
        diagnostics, solid phase, and others), target disease indication
        (influenza, pneumonia, and tuberculosis), type of sample (blood,
        cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine,
        and others), sensitivity range (&lessThan;90%, 90-95%, and >95%),
        specificity range (&lessThan;90%, 90-95%, and >95%), and turnaround time
        (5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In
        addition, the report presents the details of the companies developing
        these point-of-care diagnostics, including information on year of
        establishment, company size and location of headquarters.
    --  A detailed review of the overall landscape of point-of-care diagnostics
        for HIV/AIDS and hepatitis, providing information on current development
        status of point-of-care diagnostics (under development, research use
        only, and available), type of product (test and device / platform), type
        of technology (flow-through, fluorescence immunoassay, lateral flow,
        molecular diagnostics, solid phase, vertical flow, and others), target
        disease indication (hepatitis A, hepatitis B, hepatitis C, and
        HIV/AIDS), type of sample (blood, feces, oral fluid, and urine),
        sensitivity range (&lessThan;90%, 90-95%, and >95%), specificity range
        (&lessThan;90%, 90-95%, and >95%), and turnaround time (?5 minutes,
        >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report
        presents the details of the companies developing these point-of-care
        diagnostics, including information on year of establishment, company
        size and location of headquarters.
    --  A detailed study of the overall landscape of point-of-care diagnostics
        for infectious diseases, featuring analyses based on a number of
        relevant parameters, such as type of technology (flow-through,
        fluorescence immunoassay, lateral flow, molecular diagnostics, solid
        phase, vertical flow, and others), target disease indication
        (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza,
        malaria, pneumonia, tuberculosis, and zika), sensitivity range
        (&lessThan;90%, 90-95%, and >95%), specificity range (&lessThan;90%,
        90-95%, and >95%), and turnaround time (5 minutes, >5-15 minutes, >15-30
        minutes, and >30 minutes).
    --  An analysis of the partnerships that have been inked by stakeholders in
        this domain, during the period between January 2018 and July 2020,
        covering distribution and supply agreements, product development and
        commercialization agreements, commercialization agreements, mergers and
        acquisitions, product development and manufacturing agreements, research
        and development agreements, and product / technology integration
        agreements.
    --  A detailed analysis on acquisition targets, taking into consideration
        the historical trend of the activity of the companies that have acquired
        other firms since 2018, and offering a means for other industry
        stakeholders to identify potential acquisition targets.

For more information about this report visit https://www.researchandmarkets.com/r/e0vclw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/point-of-care-diagnostics-market-for-infectious-diseases-2030-301202021.html

SOURCE Research and Markets